Federal Court Calls PAMA Rule “Arbitrary,” but Refuses to Strike It Down
D.C. Circuit Court of Appeals agrees with lab industry that CMS got Medicare lab pricing all wrong, but says it’s unable to intervene.
Already a member? Log in here
Guidance on HIPAA Abortion Privacy Rights Post-Roe-v-Wade
Loss of constitutional abortion rights undermines privacy protection of patients seeking reproductive care.
Already a member? Log in here
How the Roe v. Wade Ruling Will Impact Prenatal Testing
Without abortion rights, basic lab testing applications for those who are or want to become pregnant have new and ominous legal implications.
Already a member? Log in here
Congress Acts to End PAMA Price Cutting Reign of Terror
After years of resistance, the lab industry’s hopes and prayers for relief from the flawed pricing scheme may soon be answered.
Already a member? Log in here
HHS Scrambles to Deal with Aftermath of Roe v. Wade Revocation
Now that the Supreme Court has revoked Roe v. Wade, HHS must rework policies, programs, and procedures related to reproductive rights.